Showing results (231-240 of 261) with videos related to
Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trialPhilippe Armand, Arnon Nagler, Edie A Weller, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research AnalysisNilanjan Ghosh, Reem Karmali, Vanderson Rocha, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2017
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for LymphomaChristopher J Gibson, R Coleman Lindsley, Vatche Tchekmedyian, et al.The Oncologist|July 29, 2020
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent TherapyNicole A Carreau, Orrin Pail, Philippe Armand, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2018
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin LymphomaMargaretha G M Roemer, Robert A Redd, Fathima Zumla Cader, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 14, 2019
Management of Immunotherapy-Related Toxicities, Version 1.2019John A Thompson, Bryan J Schneider, Julie Brahmer, et al.Blood Advances|March 19, 2026
Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapyRan Xu, Gongwei Wu, Siobhan Rice, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2020
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020John A Thompson, Bryan J Schneider, Julie Brahmer, et al.The Journal of Clinical Investigation|August 6, 2013
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cellsUte E Burkhardt, Ursula Hainz, Kristen Stevenson, et al.Journal of the National Comprehensive Cancer Network : JNCCN|April 7, 2022
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in OncologyJohn A Thompson, Bryan J Schneider, Julie Brahmer, et al.Pageof 27